This fund's holdings profile is similar to BBH, as GILD, AMGN, and BIIB all find their way into the top five. However, the top holding here is Regeneron (Nasdaq: REGN-Free Report), while Celgene (Nasdaq: CELG-Free Report) also finds its way into the fourth position at roughly 6.7% of assets (see Forget Big Pharma It Is Time for a Biotech ETF).
In terms of performance, this ETF has also been a solid performer, adding a whopping 30% over the past six months. The ETF has also done quite well in the trailing one year time frame, gaining an impressive 44.9% in that period.
For an equal weight approach to investing in biotechnology, investors have FBT a fund that tracks the Amex Biotechnology Index. Investors have to pay a bit more for this equal weight exposure though, as costs come in at 60 basis points a year, though volume and assets are still solid.
This approach also results in a bit of a value tilt, though growth stocks still make up a majority of assets in this ETF. Additionally, large caps make up just 40% of the fund, so there is definitely a tilt towards small companies that could
|SOURCE Zacks Investment Research, Inc.|
Copyright©2012 PR Newswire.
All rights reserved